The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays
- PMID: 11730845
- DOI: 10.1016/s0022-1759(01)00499-9
The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays
Abstract
ELISPOT assays are increasingly used for a direct detection and quantification of single antigen-specific T cells in freshly isolated peripheral blood mononuclear cells (PBMC). They are particularly attractive for the monitoring of specific T lymphocyte responses in clinical trials assessing antigen-specific immunizations in patients with cancer or chronic viral infections. However, one major limitation for the broad clinical implementation of ELISPOT assays is the lack of an inexhaustible source of suitable HLA-matched antigen-presenting cells (APC). Currently available allogeneic or xenogeneic APC (such as the human lymphoid hybrid T2 or HLA-transfected insect cells) can either lead to strong background spot production by APC-reactive T lymphocytes or have a low antigen presentation capability. Both phenomena can prevent the detection of low frequency T cell responses in PBMC. In search of alternative APC for ELISPOT assays, the human chronic myelogenous leukemia cell line K562 that per se does not express HLA class I and class II molecules on the cell surface was transfected with the HLA-A*0201 gene. Clonal HLA-A*0201-expressing K562 (K562/A*0201) cells were able to process and present endogenously expressed and exogenously loaded melanoma peptide antigens to HLA-A*0201-restricted cytolytic T lymphocyte clones in cytotoxicity and IFN-gamma ELISPOT assays. K562/A*0201 cells were then used as APC in IFN-gamma spot assays to detect ex vivo CD8(+) T lymphocytes responsive to known HLA-A*0201-binding peptide epitopes derived from cytomegalovirus, Epstein-Barr virus, influenza virus and melanoma in PBMC from HLA-A*0201-positive donors. In the majority of cases, peptide-pulsed K562/A*0201 cells were similarly efficient in the ability to visualize single antigen-specific CD8(+) T lymphocytes when compared to T2 cells. However, in contrast to T2, background reactivity of CD8(+) T cells responsive to unpulsed K562/A*0201 was regularly found to be negligible, thereby enhancing the sensitivity of the ELISPOT assay, particularly in donors with strong anti-T2 reactivity. K562 cells transfected with HLA-A*0201 or other HLA genes can serve as standard APC for monitoring T lymphocyte responses against tumor and viral peptide antigens.
Similar articles
-
Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay.J Immunol Methods. 2000 Feb 3;234(1-2):1-12. doi: 10.1016/s0022-1759(99)00203-3. J Immunol Methods. 2000. PMID: 10669764
-
The use of clonal mRNA as an antigenic format for the detection of antigen-specific T lymphocytes in IFN-gamma ELISPOT assays.J Immunol Methods. 2004 Apr;287(1-2):125-36. doi: 10.1016/j.jim.2004.01.026. J Immunol Methods. 2004. PMID: 15099761
-
In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring.Cytotherapy. 2006;8(5):498-508. doi: 10.1080/14653240600868262. Cytotherapy. 2006. PMID: 17050255 Clinical Trial.
-
Quantification of tumor-specific T lymphocytes with the ELISPOT assay.J Immunother. 2000 May-Jun;23(3):289-95. doi: 10.1097/00002371-200005000-00001. J Immunother. 2000. PMID: 10838657 Review.
-
Antigen presenting cells integrate opposing signals from CD4+ and CD8+ regulatory T lymphocytes to arbitrate the outcomes of immune responses.Hum Immunol. 1999 Jul;60(7):533-61. doi: 10.1016/s0198-8859(99)00045-2. Hum Immunol. 1999. PMID: 10426271 Review.
Cited by
-
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.Nat Med. 2012 Aug;18(8):1254-61. doi: 10.1038/nm.2883. Epub 2012 Jul 29. Nat Med. 2012. PMID: 22842478 Clinical Trial.
-
Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells.Sci Rep. 2025 Apr 7;15(1):11894. doi: 10.1038/s41598-025-92209-z. Sci Rep. 2025. PMID: 40195438 Free PMC article.
-
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.Mol Ther. 2007 May;15(5):981-8. doi: 10.1038/mt.sj.6300134. Epub 2007 Mar 20. Mol Ther. 2007. PMID: 17375070 Free PMC article.
-
Gene Expression-Based Identification of Antigen-Responsive CD8+ T Cells on a Single-Cell Level.Front Immunol. 2019 Nov 6;10:2568. doi: 10.3389/fimmu.2019.02568. eCollection 2019. Front Immunol. 2019. PMID: 31781096 Free PMC article.
-
Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.Hum Gene Ther. 2013 Feb;24(2):220-37. doi: 10.1089/hum.2012.128. Hum Gene Ther. 2013. PMID: 23311414 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials